How Patients with dMMR/MSI-H Tumors Can Benefit from Immunotherapy?
DNA mismatch repair (MMR) is a process that plays a key role in maintaining genomic stability by recognizing and repairing base-base mismatches and insertion/deletion of DNA generated during replication and recombination. Defects in MMR are associated with genome-wide instability and the progressive accumulation of mutations, especially regions of simple repetitive DNA sequences known as microsatellites, resulting in MSI.
In an ESMO session titled “Biomarkers for cancer immunotherapy", experts discussed how patients with dMMR/MSI-H tumors can benefit from immunotherapy. Chaired by Prof. Thierry Andre’, the session saw participation from Dr. Anna Tinker, University of British Columbia Vancouver, Canada, and Prof. Josef Ruschoff Targos, Molecular Pathology GmbH Kassel, Germany.